SFX by Ex Libris Inc.

Title:	The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-κB signalling
Source:	Embo Journal [0261-4189] Shembade, Noula yr:2009

Basic

Full text

Full text available via PubMed Central

Year:

Volume:

Issue:

Start Page:

Full text available via Wiley Online Library Full Collection 2019

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Mitsiades, Constantine S S. "The Akt pathway: molecular targets for anti-cancer drug development." Current cancer drug targets 4.3 (2004): 235-56.
description	2.	Pujari, R. "A20-mediated negative regulation of canonical NF-κB signaling pathway." Immunologic research 57.1-3 (2013): 166-71.
description	3.	Inoue Yamauchi, A. "Depletion of mitochondrial fission factor DRP1 causes increased apoptosis in human colon cancer cells." Biochemical and biophysical research communications 421.1 (2012): 81-85.
description	4.	Turecek, P L. "Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13." Journal of thrombosis and haemostasis 1.1 (2003): 187-9.
description	5.	Koenen, R. "Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice." Nature Medicine 15.1 (2009): 97-103.
description	6.	Webb, Nancy R R. "Getting to the core of atherosclerosis." Nature medicine 14.10 (2008): 1015-1016.
description	7.	"Resistin causes G1 arrest in colon cancer cells through upregulation of SOCS3." FEBS letters. 591.10: 1371-1382.
description	8.	Karthikeyan, C. "IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells." Bioorganic & medicinal chemistry 23.3 (2015): 602-611.
description	9.	Barrows, Brad D. "Use of the ADAMTS13 Activity Assay Improved the Accuracy and Efficiency of the Diagnosis and Treatment of Suspected Acquired Thrombotic Thrombocytopenic Purpura." Archives of pathology & laboratory medicine 138.4 (2014): 546-549.
description	10.	Alvarez, F. "Structural Studies of Dynamin-Related Protein 1 (DRP1) Provide Mechanistic Insight into Mitochondrial Fission." Biophysical journal 104.2; SUPP/1 (2013): 351-351.
description	11.	Ma, A. "A20: linking a complex regulator of ubiquitylation to immunity and human disease." Nature reviews. Immunology 12.11 (2012): 774-785.
description	12.	Ginsberg, Stephen D. "Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease." Journal of chemical neuroanatomy 42.2 (2011): 102-110.
description	13.	Verstrepen, L. "Expression, biological activities and mechanisms of action of A20 (TNFAIP3)." Biochemical Pharmacology 80.12 (2010): 2009-2020.
description	14.	Podbielska, M. "Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?" Multiple Sclerosis 15.9 (2009): 1011-1029.
description	15.	Wagner,, Erwin F., Erwin F. "Signal integration by JNK and p38 MAPK pathways in cancer development." Nature Reviews. Cancer 9.8 (2009): 537-549.
description	16.	Peer, W. "Synaptic inhibition of Purkinje cells mediates consolidation of vestibulo-cerebellar motor learning." Nature Neuroscience 12.8 (2009): 1042-1049.
description	17.	Barberis, A. "Searching for the most effective screening system to identify cell-active inhibitors of beta-secretase." Biological Chemistry 385.6 (2004): 481-5.
description	18.	Handel, T. "Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines." Proceedings of the National Academy of Sciences of the United States of America 100.4 (2003): 1885-1890.
description	19.	Watts, A. "Inflammation as a potential mediator for the association between periodontal disease and Alzheimer's disease." Neuropsychiatric Disease and Treatment 4.5 (2008): 865-876.
description	20.	Pisl, I. "Possibilities and limits of treatment in patients with thrombotic thrombocytopenic purpura." Intensive care medicine 26.11 (2000): 1690-3.